Pneumonia (COVID-19) caused by the New Coronavirus (CCP) continues to spread, with 158,312,868 confirmed cases and 3,296,591 cumulative deaths worldwide as of 10:00 on the 9th; China has 103,796 confirmed cases and 4,858 deaths across the country; Taiwan currently has 1,183 confirmed cases and 12 deaths.
The Deutsche Welle (DW) reports that Nepal, located in the Himalayas, has seen a rapid rise in the new epidemic due to the country’s special links and relations with India, with as many as 31,806 new cases confirmed in Nepal over the past week, with a large number of cases concentrated in the capital Kathmandu, leaving the country facing a severe epidemic prevention test.
Although the current Prime Minister Kadgar Oli (K. P. Shari) has been in charge of the epidemic, the country is facing a serious challenge. Although the current Prime Minister K. P. Sharma Oli stressed to foreign media that the government has a plan for the country’s epidemic and can be controlled in a short period of time, there is still concern that Nepal’s domestic medical resources and the number of vaccines currently available do not seem to be sufficient to stabilize the fight against the rapidly deteriorating new pneumonia epidemic.
As of the 9th, Nepal has a cumulative total of 385,890 confirmed cases and 3,632 people have died of the disease; 8,287 new cases have been diagnosed in the last 24 hours.
Same as India, Nepal also in the outbreak of the plight of oxygen supply shortage. (Thomson Reuters)
As the epidemic worsens again and the parties begin to investigate the “cause”, a scandal has broken out in Nepal, where the procurement of the new crown vaccine from India has been subject to a commission increase by the other company, resulting in the country not having immediate access to the full amount of vaccine.
An unnamed health ministry official told the media that the Nepalese government purchased the new crown vaccine developed by the Serum Institute of India from India in early March, when they signed a contract with a pharmaceutical company in Pune to purchase the first 2 million doses of the vaccine at a unit price of US$4. But the actual amount paid was $5.50 per dose because they were “required” to pay a commission.
“We reacted and protested several times, asking the other companies to sell directly to their counterparts and not through intermediate agents, but they insisted that they would not.”
As the epidemic rapidly worsened in the capital Kathmandu, large numbers of people fled by bus overnight. (Thomson Reuters)
In the face of the allegations and revelations in the Nepalese media, the Indian Serum Institute has not yet made any response or explanation, which also allows the two countries to deal with the tricky epidemic at the same time, but also must be distracted to look at, this gray trading scandal under the table.
Recent Comments